ReviewClinical pharmacokinetics2003
Pharmacology of anticancer drugs in the elderly population.
Review in Clinical pharmacokinetics, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Electroacupuncture and Transcutaneous Electrical Acupoint Stimulation for Perioperative Neurocognitive Disorder in Older Patients Undergoing Cardiac Surgery: Protocol for Systematic Review and Meta-Analysis.JMIR research protocols · 2024Article
- A case report: deep and durable response to low-dose lenvatinib and tislelizumab in an elderly patient with advanced intrahepatic cholangiocarcinoma.Frontiers in pharmacology · 2024Article
- Acute, Subchronic, and Chronic Complications of Radical Prostatectomy Versus Radiotherapy With Hormone Therapy in Older Adults With High-Risk Prostate Adenocarcinoma.Frontiers in oncology · 2022Article
- Diabetes and Cancer: Metabolic Association, Therapeutic Challenges, and the Role of Natural Products.Molecules (Basel, Switzerland) · 2021Review
- Excess mortality and undertreatment in elderly lung cancer patients: treatment nihilism in the modern era?ERJ open research · 2021Article
- Improving health engagement and lifestyle management for breast cancer survivors with diabetes.Contemporary clinical trials · 2020Article
- Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Elderly Patients with Metastatic Breast Cancer: A Meta-Analysis.Journal of clinical medicine · 2019Article
- Spanish list of potentially inappropriate drugs in the elderly (ES-PIA project).European journal of clinical pharmacology · 2019Article
- Systemic Treatment of Prostate Cancer in Elderly Patients: Current Role and Safety Considerations of Androgen-Targeting Strategies.Drugs & aging · 2019Review
- Article
- Toxicity of Cancer Therapies in Older Patients.Current oncology reports · 2018Review
- Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review.Journal of gastrointestinal cancer · 2017Review
- Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Article
- Effect of age on drug metabolism in women with breast cancer.Expert opinion on drug metabolism & toxicology · 2015Review
- Prevalence of renal insufficiency in elderly cancer patients in a tertiary cancer center.Einstein (Sao Paulo, Brazil) · 2014Article
- Combination of micellar electrokinetic and high-performance liquid chromatographies to assess age-related changes in the in vitro metabolism of Fischer 344 rat liver.The journals of gerontology. Series A, Biological sciences and medical sciences · 2011Article
- Cardiovascular complications of breast cancer therapy in older adults.The oncologist · 2011Review
- Evaluation of the Reliability of Electronic Medical Record Data in Identifying Comorbid Conditions among Patients with Advanced Non-Small Cell Lung Cancer.Journal of cancer epidemiology · 2011Article
- Treatment of diffuse large B-cell lymphoma in the elderly: strategies integrating oncogeriatric themes.Current oncology reports · 2008Review
- Do we learn the right things from clinical trials?European journal of clinical pharmacology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modifications to bodily functions and physiology are known to occur with age. These changes can have a considerable impact on the pharmacokinetic processes of absorption, distribution, metabolism and excretion and the pharmacodynamic properties of administered drugs. For many drugs with a high therapeutic index, this will be clinically unimportant, but for anticancer drugs, which usually have a low therapeutic index, these pharmacological changes can lead to dramatic consequences, such as excessive drug concentrations and unacceptable toxicity, or subtherapeutic drug concentrations and ineffective treatment. Despite the increased susceptibility of the elderly to these changes, doses are rarely adapted on the basis of pharmacokinetics and pharmacodynamics, with the exception of changes secondary to altered renal function. Until recently, only a few large prospective randomised trials have provided evidence-based data for dose adaptations in elderly patients. However, with increasing knowledge of the pharmacokinetics of anticancer drugs, advances in the knowledge of pharmacokinetic behaviour with aging, and documented efficacy and toxicity data in the elderly population, it is possible to highlight aspects of prescribing anticancer drugs in the elderly. In general, and for most drugs, age itself is not a contraindication to full-dose chemotherapy. The main limiting factors are comorbidity and poor functional status, which may be present in a significant number of the elderly population. Elderly patients with cancer are part of the daily practice of oncologists, but currently clinicians can often only estimate whether dose modification is advantageous for the elderly. This review attempts to elucidate the factors that can influence the pharmacokinetics of anticancer drugs frequently used in the elderly, and the clinical or biochemical parameters that form the basis for dose adjustments with age.
Indexed as
Identifiers
14606930What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.